FY2022 · ended Dec 31, 2022 · Revenue $2.30M, -91.6% YoY · Filed Mar 29, 2024
Elicio Therapeutics, Inc. (ELTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$37.0 million. As of Sep 30, 2026 it held $30.9 million in cash and investments and $14.0 million in total debt.
Revenue (TTM)
$653,000
-97.7% vs year-ago TTM
Net income (TTM)
$-29.18M
-17.0% vs year-ago TTM
Operating cash flow (TTM)
$-36.97M
+5.0% vs year-ago TTM
Free cash flow
$-36.97M
+0.5% vs prior year
EPS (TTM)
$4.21
+603.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
18.70M
+1.7% vs prior year
Net cash
$16.91M
as of Sep 30, 2026
Operating margin
-2611.5%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1601485
- Former names
- Angion Biomedica Corp. (until May 30, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $27.5M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M |
| Diluted EPS | -$2.58 | -$4.25 | -$6.96 | -$89.27 | -$1.93 |
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
| Stockholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M |
| Cash and investments | $18.6M | $17.6M | $12.9M | $6.2M | $88.8M |
| Total debt | $15.1M | $6.0M | $6.9M | $3.7M | $4.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 14, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 2, 2026 | Jul 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 17, 2026 | Jun 17, 2026 |
All 382 Elicio Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.